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ABSTRACT
Objective: To study the association of anti-nucleosome (anti-NCS) antibodies in primary antiphospholipid syndrome 
(APS) and the development of systemic lupus erythematosus (SLE) during follow-up. Materials and methods: Thirty-six 
women with primary APS were evaluated prospectively for clinical features of systemic autoimmune diseases and for the 
presence of antiphospholipid antibodies, antinuclear antibodies and anti-NCS/chromatin antibodies. Results: After a mean 
follow-up period of 45.7 months, anti-NCS/chromatin antibodies were detected in only one patient (2.8%), who developed 
features of SLE including polyarthritis, lymphopenia, optic neuritis, multiple sclerosis-like lesions, and an autoantibody 
profi le suggestive of SLE. Conclusion: The frequency of anti-NCS/chromatin antibodies in primary APS patients is very 
low, and they may be associated with the development of SLE manifestations.
Keywords: antiphospholipid syndrome, systemic lupus erythematosus, anticardiolipin antibodies, lupus coagulation 
inhibitor nucleosomes.
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INTRODUCTION
The antiphospholipid syndrome (APS) is characterized by 
thrombotic manifestations and/or obstetrical morbidity in the 
presence of antiphospholipid antibodies (APL). The standard 
APL assays recommended by the latest guidelines on APS are 
the lupus anticoagulant (LAC) and enzyme immunoassays for 
antibodies against β2 glycoprotein I (anti-β2 GPI) and against 
cardiolipin (aCL) in the presence of β2 GPI. APS can occur 
as a primary disease or associated with some other systemic 
autoimmune disease, predominantly systemic lupus erythe-
matosus (SLE).1,2
SLE is characterized by a wide range of circulating autoan-
tibodies, several of which are directed against nuclear antigens.3 
In particular, chromatin antigens appear to be a preferential 
target of autoantibodies in SLE. Nucleosome is the unit of 
chromatin and consists of 146 base pairs of DNA wrapped 
around a protein core. The protein core is an octamer consist-
ing of two molecules of each of the histones H2A, H2B, H3, 
and H4.4 The frequency of autoantibodies against nucleosome 
(anti-NCS) and H1 stripped chromatin (anti-chromatin) in SLE 
varies from 50%–100% and the specifi city for SLE diagnosis 
has been reported from 90%– 99%.5–15 Anti-NCS/chromatin 
antibodies have been associated with active glomerulonephritis 
in SLE patients.6–10 
Although considered specifi c for SLE, anti-NCS/chro-
matin antibodies have been reported in other autoimmune 
conditions such as systemic sclerosis, Sjögren’s syndrome, 
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mixed connective tissue disease, and type 1 autoimmune 
hepatitis.6,8,9,16,17 There is some controversy in the literature and 
some authors believe that the fi nding of positive reactivity in 
non-lupus patients is due to heterogeneity in NCS/chromatin 
preparations and other reagents used in enzyme-linked im-
munosorbent assay (ELISA) tests.6,18–20 
Recently, different groups have reported on anti-NCS/
chromatin antibodies in primary APS.9,21,22 However, the 
prevalence of anti-NCS antibodies is wide among primary 
APS patients, ranging from 7%–77%; this may be related 
either to methodological issues in the detection of anti-NCS/
chromatin antibodies or to the inclusion of patients with 
lupus-like syndrome. Many of the anti-NCS/chromatin posi-
tive patients with primary APS were found to subsequently 
develop SLE.21,22 Thus, it is not established whether primary 
APS patients carrying anti-NCS/chromatin antibodies are in 
fact SLE patients with incipient disease. Therefore, we set to 
develop an observational prospective study to evaluate the 
frequency of anti-NCS/chromatin antibodies in patients with 
primary APS and the development of defi ned SLE or isolated 
SLE traits. 
MATERIALS AND METHODS
Sampling, recruitment and data collection
Thirty-six women meeting the Sapporo criteria for primary 
APS23 underwent clinical evaluation for manifestations of APS 
and other autoimmune diseases. Peripheral blood was ob-
tained at study entry for determination of LAC and aCL, 
anti-β2 GPI and anti-NCS/chromatin antibodies. Patients 
were prospectively evaluated for a mean of 45.7 ± 9.6 
months (range 13–56) with special attention for evidence 
of systemic autoimmune disease or the establishment of 
SLE according to the American College of Rheumatology
updated criteria for SLE classifi cation.24 Exclusion criteria 
at study entry were the presence of systemic autoimmune 
disease other than APS, chronic infection, malignancy, and 
age below 18 years. All participants signed an Informed 
Consent approved by the institutional Ethics Committee. 
Antibody assays
Anti-cardiolipin antibodies were detected using an in-house 
standard ELISA technique.25 Briefl y, ELISA plates (NUNC 
– Thermo Fisher Scientifi c Inc, Roskilde, Denmark) were 
coated (50 µL per well) with bovine cardiolipin (50 µg/mL) 
(Sigma Aldrich Inc, St Louis, USA) overnight at 4 ºC. After 
blocking with 100 µL of 10% adult bovine serum (ABS) in 
phosphate buffered saline pH 7.4 (PBS) for 2 hours at room 
temperature (RT), 50 µL of patient serum diluted 1:50 in 10% 
ABS in PBS were added to duplicate wells and incubated 
overnight at 4 °C. Plates were then washed three times with 
PBS and wells received alternatively 50 µL anti-IgM or anti-
IgG peroxidase-conjugates (Calbiochem, La Jolla, CA, USA) 
diluted 1:4,000 and 1:5,000 in PBS, respectively, and then 
were incubated for 90 minutes at RT. After two additional 
washing steps as before, 50 µL p-nitrophenyl phosphate 
disodium in diethanolamine buffer (pH 9.8) were added to 
the wells. 
The optic density (OD) was determined by spectropho-
tometry at 450 nm wave length at 15-minute intervals until the 
standard positive sample reached an OD between 1,000 and 
1,200. The calibration curve was based on international APL 
standards (Louisville APL Diagnostics Inc, Doraville, GA, 
USA). All samples were processed in duplicate. Results were 
expressed in GPL and MPL units for IgG and IgM aCL, respec-
tively, and positive values were considered when above 20 GPL 
or 20 MPL units. LAC was detected using activated partial 
thromboplastin time (APTT – Diagnostica Stago, France) and 
diluted Russell’s viper venom time (dRVVT – Trinity Biotech, 
Wiclow, Ireland, UK) according to international guidelines.26 
Serum IgG and IgM anti-β2 GPI were detected by ELISA (The 
Binding Site, Birmingham, UK), according to the manufac-
turer’s instructions with cutoff values of 10 U/mL for IgM and 
20 U/mL for IgG.
Anti-NCS/chromatin antibodies were detected by ELISA 
(INOVA Diagnostics, San Diego, CA, USA), according to 
the manufacturer’s instructions. Antinuclear antibodies 
(ANA) were determined by indirect immunofl uorescence 
on HEp-2 cells (Bion, Des Plaines, IL, USA) at a screen-
ing dilution of 1:80, according to standard protocol.27,28 
Anti-double stranded DNA (dsDNA) tests were performed 
by indirect immunofl uorescence using Crithidia luciliae 
as substrate; anti-extractable nuclear antigens (ENA) were 
detected by double immunodiffusion technique and in-
cluded anti-SSA/Ro, anti-SSB/La, anti-Sm, and anti-RNP 
antibodies. The Western blot technique was used to detect 
at least one band of three ribosomal P proteins P0 (38 kD), 
P1 (19 kD), and P2 (17 kD). 
Statistical analysis
Statistical analysis was carried out with SPSS 10.0 for 
Windows, Chicago, USA. Results were expressed as total 
number and percentage for categorical data and as mean and 
standard deviation (SD) for continuous variables. 
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RESULTS
Features of primary APS patients
Thirty-six women with primary APS with a mean age of 
38.4 ± 11.8 years participated in this study. Fifteen (42%) 
were Caucasian-descendants and 21 (58%) were African-
descendants. Previous arterial thrombosis episodes occurred 
in 13 patients (36.1%) being stroke the most frequent mani-
festation, occurring in 11 (84.6%) of these cases. Previous 
venous thrombotic episodes occurred in 17 patients (47.2%) 
mostly in the lower limbs (13 patients, 76.4%). Seventeen 
patients (47.2%) presented pregnancy morbidity, which was 
the only APS manifestation in six of them (Table 1). Along 
the follow-up period, aCL was present in 31 patients (86.1%), 
IgG aCL was found in 28 (77.8%), and IgM aCL in eight pa-
tients (22.2%). Eleven patients (30.6%) had a positive LAC 
test. Anti-β2 GPI antibodies were detected in eight patients 
(22.2%): IgM anti-β2 GPI in fi ve (13.9%) and IgG anti-β2 
GPI in six patients (16.7%). The concomitant presence of 
the three APS-associated autoantibodies (aCL, LAC, and 
anti-β2 GPI antibodies) occurred in six cases (16.7%) (Table 
1). ANA was detected in 12 patients (33.3%) and the most 
frequent ANA pattern was the nuclear fi ne speckled pattern, 
that occurred at 1/320 titer in eight patients. Other ANA 
patterns, such as nuclear homogeneous (two cases), nuclear 
envelope (one case), and discrete cytoplasm speckles (one 
case), were also observed. 
Anti-NCS/chromatin antibodies and disease 
follow-up in primary APS patients 
Anti-NCS/chromatin antibodies were positive in only one 
patient (2.8%) with primary APS (Table 1). Considering 
that the recommended cut-off for the test is 20 IU/mL and 
strongly positive reactivity is set above 60 IU/mL, it is 
relevant to mention that this patient presented 147 IU/mL 
(Figure 1). Along the follow-up period (45.7 ± 9.6 months) 
this patient with reactivity for the anti-NCS/chromatin as-
say developed manifestations of SLE such as lymphopenia, 
polyarthritis, and neurological involvement characterized 
by optic neuritis and white matter demyelinating lesions 
resembling multiple sclerosis on brain MRI. She also 
developed an autoantibody profile compatible with SLE, 
including a 1:1280 antinuclear test (Hep-2 ANA) with 
homogeneous pattern, anti-dsDNA 1/10, anti-SS-A/Ro and 
anti-ribosomal P antibodies. This patient had a non-reactive 
test for anti-aquaporin 4 antibody. Among patients with no 
reactivity for anti-NCS/chromatin antibodies, two devel-
oped rheumatoid-like polyarthritis and had non-reactive 
tests for rheumatoid factor and cyclic citrullinated peptide 
antibody. One of them was treated with corticosteroids and 
methotrexate and another one with methotrexate and leflu-
nomide. One death occurred due to myocardial infarction 
in one patient after a mean follow-up time of 13 months. 
No other patient developed symptoms and signs suggestive 
of systemic involvement. No other patient was reactive for 
anti-dsDNA and ENA.
Table 1
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Pregnancy morbidity 17 (47.2%)
APS-related autoantibodies (frequency)
        LAC
        IgG aCL                      
        IgM aCL
        Anti-β2 GPI
        All three antiphospholipid antibodies
11 (30.6%)
28 (77.8%)
  8 (22.2%)
  8 (22.2%)
  6 (16.7%)
Anti-nucleosome/chromatin antibodies (frequency)
        Anti-chromatin   1 (2.8%)
Figure 1
Magnitude of IgG anti-NCS/chromatin antibody reactivity in 
primary APS patients. Levels between 20.0 IU/mL and 60.0 
IU/mL are considered moderately positive and levels above 
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DISCUSSION
The present study has demonstrated a low frequency of antibod-
ies against chromatin components in primary APS. In fact, only 
one patient (2.8%) had a positive anti-NCS/chromatin test and 
developed SLE. The vast majority of the primary APS patients 
did not develop overt signs and symptoms compatible with SLE 
along the mean 45-month follow-up period. As an exception, 
however, the one patient with reactivity in the anti-NCS/chro-
matin assay presented lymphopenia, polyarthritis, optic neuri-
tis, white matter demyelinating lesions suggestive of multiple 
sclerosis, and an autoantibody profi le highly suggestive of SLE.
The presence of anti-NCS/chromatin antibodies in patients 
with primary APS has been subject of some controversy in 
the recent literature. Since anti-NCS/chromatin antibodies are 
considered as highly specifi c for SLE, the occurrence of these 
autoantibodies in a patient with current diagnosis of primary 
APS might indicate the possibility of progression towards SLE. 
In fact, it has been shown by one group that the prevalence 
of anti-NCS/chromatin antibodies in primary APS is low9 
and other groups associated their presence in APS patients 
with subsequent development of SLE features.21,22 Although 
the development of manifestations of APS in SLE patients 
with APL antibodies has been reported in 50%–70% of cases 
within twenty years of follow-up,1,29 the opposite is not usually 
expected. Actually, a complete picture of SLE may evolve in 
4%–10% primary APS patients, and the presence of a family 
history of SLE, Raynaud phenomenon, migraine, multiple 
sclerosis-like features, hemolytic anemia, low C3 and C4, and 
Coombs’ test positivity are recognized risk factors.30 The pres-
ent fi nding suggests that anti-NCS/chromatin antibodies might 
be included as an additional risk factor for SLE development 
in patients with a diagnosis of primary APS.
The antigenic substrate used in the anti-NCS/chromatin 
assays is relevant to the heterogeneity in results obtained by dif-
ferent authors. The commercial assay used in the present study 
was H1-stripped chromatin devoid of non-histone proteins 
(mainly oligonucleosomes) derived from calf thymus. This 
is a widely used antigen for anti-NCS/chromatin assays and 
contains most nucleosome epitopes recognized by polyclonal 
and monoclonal anti-NCS antibodies. 
The lack of standardization of serologic tests is a major 
problem for autoantibody determination.31 The antigens 
currently used for determination of anti-NCS/chromatin 
antibodies include H1-stripped chromatin, polynucleosomes 
devoid of H1, and mononucleosomes with or without H1. 
In addition, there is variation in the biochemical condi-
tions for antigen purifi cation and in the raw source used for 
antigenic preparation. Finally there is heterogeneity in the 
conditions established in the various immunoassays. This 
overall heterogeneity implies that the different assays do 
not detect exactly the same autoantibody population and this 
may contribute to the partially confl icting results observed 
in the literature.32 
In conclusion, the present study showed a low frequency 
of antibodies against NCS/chromatin in patients with primary 
APS and those autoantibodies may be associated with the 
development of SLE features in patients with a diagnosis of 
primary APS. Further multicentric and longitudinal studies 
should be performed to confi rm this fi nding. 
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